Your browser doesn't support javascript.
loading
FABP4 as a key determinant of metastatic potential of ovarian cancer.
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta; Rupaimoole, Rajesha; Ivan, Cristina; Wu, Sherry Y; Bayraktar, Emine; Nagaraja, Archana S; Mangala, Lingegowda S; Zhang, Xinna; Haemmerle, Monika; Hu, Wei; Rodriguez-Aguayo, Cristian; McGuire, Michael; Mak, Celia Sze Ling; Chen, Xiuhui; Tran, Michelle A; Villar-Prados, Alejandro; Pena, Guillermo Armaiz; Kondetimmanahalli, Ragini; Nini, Ryan; Koppula, Pranavi; Ram, Prahlad; Liu, Jinsong; Lopez-Berestein, Gabriel; Baggerly, Keith; S Eberlin, Livia; Sood, Anil K.
Afiliação
  • Gharpure KM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Pradeep S; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Sans M; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
  • Rupaimoole R; Department of Chemistry, The University of Texas at Austin, Austin, TX, 78712, USA.
  • Ivan C; Department of Pathology and Institute of RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center, Harvard Medical School, Boston, MA, 02215, USA.
  • Wu SY; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
  • Bayraktar E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Nagaraja AS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Mangala LS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Zhang X; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Haemmerle M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Hu W; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
  • Rodriguez-Aguayo C; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
  • McGuire M; Martin-Luther-University Halle-Wittenberg, Institute of Pathology, 06112, Halle (Saale), Germany.
  • Mak CSL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Chen X; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
  • Tran MA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Villar-Prados A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Pena GA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Kondetimmanahalli R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Nini R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Koppula P; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
  • Ram P; Department of Pharmacology, Ponce Health Sciences University, Ponce, 00716, Puerto Rico.
  • Liu J; The University of Texas at Austin, Austin, TX, 78712, USA.
  • Lopez-Berestein G; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Baggerly K; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • S Eberlin L; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Sood AK; Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Nat Commun ; 9(1): 2923, 2018 07 26.
Article em En | MEDLINE | ID: mdl-30050129
ABSTRACT
The standard treatment for high-grade serous ovarian cancer is primary debulking surgery followed by chemotherapy. The extent of metastasis and invasive potential of lesions can influence the outcome of these primary surgeries. Here, we explored the underlying mechanisms that could increase metastatic potential in ovarian cancer. We discovered that FABP4 (fatty acid binding protein) can substantially increase the metastatic potential of cancer cells. We also found that miR-409-3p regulates FABP4 in ovarian cancer cells and that hypoxia decreases miR-409-3p levels. Treatment with DOPC nanoliposomes containing either miR-409-3p mimic or FABP4 siRNA inhibited tumor progression in mouse models. With RPPA and metabolite arrays, we found that FABP4 regulates pathways associated with metastasis and affects metabolic pathways in ovarian cancer cells. Collectively, these findings demonstrate that FABP4 is functionally responsible for aggressive patterns of disease that likely contribute to poor prognosis in ovarian cancer.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteínas de Ligação a Ácido Graxo Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Proteínas de Ligação a Ácido Graxo Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article